ABBOTT LABORATORIES WKN: 850103 ISIN: US0028241000 Kürzel: ABT Forum: Aktien Thema: Hauptdiskussion

Aussichten begeistern nicht gerade. Aber ich finde den Kursrutsch auch übertrieben.

Mal sehen wo der Kurs heute Abend steht. Die Hälfte des Verlusts ist dann vermutlich schon wieder aufgeholt.

Unterstützung hält. Falls der Markt da jetzt nicht total verrückt spielt ist hier eine super kaufgelegenheit

Abbott Laboratories Q2 2024 Adj EPS $1.14 Beats $1.10 Estimate, Sales $10.377B Beat $10.371B Estimate

- Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items. - Sales of $10.4 billion - Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS of $4.61 to $4.71. "We achieved another quarter of strong growth in our underlying base business," said Robert B. Ford, chairman and chief executive officer, Abbott. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance."

gute zahlen passt weitermachen

$ABT | Abbott Laboratories Q1 Earnings Highlights: 🔹 Adj. EPS: $0.98 (Est. $0.95) 🟢 🔹 Revenue: $9.96B (Est. $9.89B) 🟡 🔹 Organic Sales Growth in Q1: Up 4.7% Narrowed Guidance: 🔹 FY'24 Adj. EPS: $4.55 to $4.70 (Prev. $4.50 to $4.70, Est. $4.62) 🟡 🔹 FY'24 GAAP EPS: $3.25 to $3.40 🔸 Q2'24 Adj. EPS: $1.08 to $1.12 (Est. $1.12) 🔴 Operational Highlights: 🔹 FY 2024 Organic Sales Growth Forecast: 8.5% to 10% (Excluding COVID-19 related sales) Key Metrics and Updates: 🔹 Adjusted Net Debt to EBITDAR: 2.7x 🔹 Specified Items Impact (mostly amortization, restructuring): $1.30 per share for FY Strategic Developments: 🔸 Raised the midpoint of full-year guidance ranges, reflecting confidence in ongoing business performance. 🔸 Noted strong performance particularly in medical device sales contributing to earnings beat.

Na dann schau dir mal die heutige Kursentwicklung von Reckitt Benkiser. Betrifft dasselbe Gerichtsurteil. Da ist das hier ja ein Ponyhof dagegen.

Hmm eher net so geil

https://www.xm.com/research/markets/allNews/reuters/reckitt-unit-hit-with-60-million-verdict-in-enfamil-baby-formula-case-in-illinois-53791077

Das unternehmen ist doch der Besitzer Hersteller von libre 3 ?

$ABT ABBOTT LABORATORIES JUST REPORTED EARNINGS! 👇🏽 Revenue of $10.24B beats by $50M ✅ EPS of $1.19 in-line 😃 Shares down 2% 📉

$ABT with a 7.8% dividend increase! Dividend King ✅ Undervalued per DYT ✅ 5Y Dividend CAGR > 10% ✅ FCF Payout < 50% ✅ ROIC > 10% ✅ Net Debt to EBITDA < 1 ✅ 🥰🥰🥰🥰

?